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Who should get a liver graft?q
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CH-8091 Zu¨rich, SwitzerlandThere is always a risk of controversy and conﬂict
when demand drastically exceeds supply. This is the case
with liver allografts in most countries. The success of
orthotopic liver transplantation (OLT), which has
reached a survival rate of about 90% at 1 year and
80% at 5 years [1], has lead to the wide acceptance of
the procedure and an extension of indications and, as
a consequence, the demand for liver grafts has far outp-
aced the supply.
In this twelfth forum, Richard Freeman, in collabora-
tion with a number of experts, covers issues related to
the allocation of organs in a comprehensive and well
balanced manner. Dr. Neville Jamieson, from Cam-
bridge, UK, critically examines the two opposing sys-
tems of organ allocation, center-based (UK system) vs.
patient-based (e.g.; Eurotransplant countries or USA).
Allocation to a center, which provides much room to
choose the most appropriate recipient on the center list
is applicable only in systems, where the number, locali-
zation, and activity of the respective centers are con-
trolled at a national level. However, issues of access to
organs as well as the ethical requirement to separate
organ donation from allocation have brought center-
based allocation to the end of the road, even in the
British system. Allocation to a speciﬁc patient based
on a calculated score, such as the model for end-stage
liver disease (MELD), has enabled the distribution of0168-8278  2009 European Association for the Study of the Liver Publish.
doi:10.1016/j.jhep.2009.01.012
q The author declares that he does not have anything to disclose
regarding funding from industries or conﬂict of interest with respect to
this manuscript.
* Tel.: +41 44 2552300; fax: +41 44 2554449.
E-mail address: clavien@chir.uzh.ch
Abbreviations: MELD, model for end-stage liver disease; OLT,
orthotopic liver transplantation; HCC, hepatocellular carcinoma.organs among many centers resulting in reduced death
on the waiting list without an increase in mortality [2].
However, this simple allocation system, prioritizing the
sickest patient, is far from perfect [3]. The ﬁnal goal
remains optimal donor to recipient matching to maxi-
mize organ usage, fair distribution and excellent results.
Dr. Douglas Schaubel, from the Department of Biosta-
tistics in Ann Arbor, Michigan, USA, addresses the
issue of urgency vs. utility vs. survival beneﬁts. Knowl-
edge of these deﬁnitions is crucial when discussing allo-
cation policies of grafts, particularly when there is a
deﬁnite mortality rate on the waiting list and following
OLT. The MELD system is critically evaluated in light
of those perspectives. Dr. Robert Porte, from Gronin-
gen, the Netherlands, covers the challenging topic of
‘‘extended criteria grafts”. Recent studies have high-
lighted the diversity of donor organ quality and associ-
ated risks of malfunction after OLT, and thereby the
need to consider those risks in the allocation scheme
[4,5]. Deﬁnition, associated risks, and the question of
how to adjust for the allocation of ECD grafts remains
a challenge, which may also lead to developing protec-
tive strategies to reduce graft injury during organ preser-
vation and after reperfusion. Dr. Richard Freeman from
Boston, USA, covers the topic of allocating liver grafts
to patients with hepatocellular carcinoma (HCC). This
topic has also been covered in previous fora [6–8]. Stag-
ing as well as factors predicting drop out from the wait-
ing list, and the MELD system, adjusted to the increased
risk of death related to a HCC (HCC-MELD), are dis-
cussed in detail. Finally, Dr. Frederico Villamil, from
Buenos Aires, Argentina, addresses the diﬃcult issue
of which patients with fulminant liver failure should
get a graft, and if so, on the basis of which priority. Aed by Elsevier B V. . Open access under CC BY-NC-ND license.
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tiate between those who may need or not need an OLT.
It is also highlighted that reﬁned criteria, diﬀerent from
the MELD system, are needed to prioritize patients with
acute liver failure.
I would like to thank Dr. Richard Freeman and his
co-authors for their excellent and critical coverage of a
delicate and diﬃcult topic, where complex medical, eth-
ical, social and economic issues are interrelated. I hope
this forum will provide new insight into this topic, and
serve as a platform for discussion in a variety of health
care systems.
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